Clinical Review:Topical Ophthalmic Use of Cyclosporin A

YILDIRIM C. A., Stern M., Akpek E. K.

OCULAR IMMUNOLOGY AND INFLAMMATION, cilt.18, sa.5, ss.352-361, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 18 Sayı: 5
  • Basım Tarihi: 2010
  • Doi Numarası: 10.3109/09273948.2010.498657
  • Dergi Adı: OCULAR IMMUNOLOGY AND INFLAMMATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.352-361
  • Anahtar Kelimeler: atopic keratoconjunctivitis, blepharitis, cyclosporine A, dry eye syndrome, vernal keratoconjunctivitis
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Cyclosporine A (CsA) is an immunomodulatory agent that primarily inhibits the proliferation and action of T cells. Systemic CsA has been used successfully in solid organ transplantation and noninfectious uveitis. Topical CsA with various formulations has been used in the field of ocular surface diseases since early 1980s. An ophthalmic emulsion 0.05% (Restasis, Allergan, Irvine, CA), was approved by the United States Food and Drug Administration in 2003 to treat dry eye syndrome. This article aims to evaluate the peer-reviewed published scientific literature and to define well-established uses of CsA eyedrops in the field of ocular surface diseases.